Want to see JP:4263 full AI Analyst Report?
Top Page
SUSMED,Inc.
(4263)
Select Model
Select Model
Rating:54Neutral
Price Target:
¥707.00
▼(-13.89% Downside)
Action:Reiterated
Date:07/01/26
The score is primarily held back by heavy losses and increasing cash burn despite excellent gross margins, while the debt-free balance sheet provides a meaningful offset. Technically, the stock shows near-term improvement (above 20/50-day averages) but remains below longer-term averages, limiting the technical contribution. Valuation is pressured by a negative P/E due to unprofitability and the absence of dividend yield support.
Positive Factors
High gross margins
Sustained ~97% gross margins indicate strong unit economics and pricing power in the core digital healthcare services. High margin structure supports scalability: as revenue grows, incremental sales should largely flow to the operating line, improving the path to durable profitability if operating costs are controlled.
Negative Factors
Deep unprofitability
Large negative net margins reflect operating losses that are structurally material relative to revenue. Persistent deep unprofitability increases the risk the business will require ongoing external funding and delays sustainable returns to investors absent clear cost structure changes or faster revenue scale.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained ~97% gross margins indicate strong unit economics and pricing power in the core digital healthcare services. High margin structure supports scalability: as revenue grows, incremental sales should largely flow to the operating line, improving the path to durable profitability if operating costs are controlled.
Read all positive factors
SUSMED,Inc. (4263) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥12.04B
Dividend YieldN/A
Average Volume (3M)121.17K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-39.26%
EPS Growth-69.48%
CountryJP
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-28.81
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
SUSMED,Inc. Business Overview & Revenue Model
Company Description
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, bre...
How the Company Makes Money
Publicly available, source-verifiable detail sufficient to describe SUSMED,Inc. (4263)’s specific revenue model (e.g., named business segments, primary product/service lines, pricing approach, or disclosed major partnerships) is not available in t...
SUSMED,Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.25M | 462.99M | 342.58M | 530.65M | 316.87M | 115.49M |
| Gross Profit | 260.05M | 450.72M | 330.85M | 522.67M | 306.50M | 105.73M |
| EBITDA | -475.95M | -289.22M | -350.22M | -43.99M | -231.11M | -275.60M |
| Net Income | -485.10M | -298.40M | -357.42M | -50.75M | -233.48M | -277.55M |
Balance Sheet | ||||||
| Total Assets | 4.22B | 4.50B | 4.93B | 5.10B | 4.94B | 1.67B |
| Cash, Cash Equivalents and Short-Term Investments | 3.96B | 4.40B | 4.85B | 5.05B | 4.90B | 1.63B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 114.37M | 132.33M | 327.79M | 230.33M | 93.34M | 97.20M |
| Stockholders Equity | 4.11B | 4.37B | 4.60B | 4.87B | 4.85B | 1.58B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -436.79M | -240.04M | 82.40M | -177.90M | -239.49M |
| Operating Cash Flow | 0.00 | -432.48M | -230.76M | 100.59M | -165.28M | -235.09M |
| Investing Cash Flow | 0.00 | -19.97M | -8.53M | -18.19M | -20.36M | -4.40M |
| Financing Cash Flow | 0.00 | 3.67M | 37.37M | 62.36M | 3.46B | 1.50B |
SUSMED,Inc. Technical Analysis
Negative
821.00
Price Trends
727.44
Negative
839.76
Negative
884.85
Negative
Market Momentum
-19.80
Positive
44.12
Neutral
48.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Negative. The current price of 821 is above the 20-day moving average (MA) of 718.30, above the 50-day MA of 727.44, and below the 200-day MA of 884.85, indicating a bearish trend. The MACD of -19.80 indicates Positive momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4263.
SUSMED,Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.21T | 24.57 | 12.38% | 1.16% | 23.33% | 21.65% | |
60 Neutral | ¥204.85B | 30.26 | ― | 0.43% | 20.95% | 13.38% | |
54 Neutral | ¥12.04B | -24.78 | ― | ― | -39.26% | -69.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥67.08B | 66.22 | 6.35% | ― | 23.30% | -56.05% | |
43 Neutral | ¥2.05B | -3.84 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:4263
SUSMED,Inc.
699.00
-212.00
-23.27%
JP:2413
M3
1,769.50
-75.35
-4.08%
JP:4480
Medley
2,089.00
-1,046.00
-33.37%
JP:4438
Welby Inc.
258.00
-96.00
-27.12%
JP:4483
JMDC Inc.
3,010.00
-990.54
-24.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.